Attaya Suvannasankha, MD
Enriched profileAssociate Professor of Medicine; Director, Multiple Myeloma Program, Division of Hematology and Oncology · Indiana University School of Medicine
Attaya Suvannasankha is Associate Professor of Medicine; Director, Multiple Myeloma Program, Division of Hematology and Oncology at Indiana University School of Medicine. OpenAlex indexes 211 publications with 3,919 citations (h-index 30); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 16 Oct 2026
Attaya Suvannasankha, M.D., is Associate Professor of Medicine at Indiana University School of Medicine. The public record shows 211 publications with 3,919 citations (h-index 30), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 15 companies, 3 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · European journal of haematology
- Top research focus: Multiple Myeloma Research and Treatments
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 54.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Sponsor: SWOG Cancer Research Network
- Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Sponsor: Attaya Suvannasankha
Industry payments
Updated 16 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$16,995openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- Janssen Biotech, Inc.Program year202511 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.9%Thalidomide Analog27.3%Lenalidomide54%Pomalyst31%Revlimid15%Part D<11 patientsKinase inhibitor2.6%Brukinsa100%Part D<11 patientsDermatology
26.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor26.6%Acyclovir100%Part D≥37 patientsAnti-infectives
11.9%Short-acting sulfonamides11.9%Sulfamethoxazole-Trimethoprim100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple Myeloma
Rlr Va Medical Center
FY2026I01CX000623 - Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple Myeloma
Rlr Va Medical Center
FY2024I01CX000623 - A Novel Agent to Suppress Tumor Growth in Bone, Prevent Cachectic Muscle Loss and Preserve Skeletal Integrity
Rlr Va Medical Center
FY2022I01BX004514
Congress activity
Updated 16 Oct 2026
49 congress contributions (2005–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma.
European journal of haematology
Article2026 - Bispecific T-cell engagers for relapsed/refractory multiple myeloma after solid organ transplantation: A case series.
Journal of investigative medicine
Case Report2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaArticle444 citations2017
- 03
- 04
- 05Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaArticle187 citations2024
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/attaya-suvannasankha-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/attaya-suvannasankha-205355259
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/attaya-suvannasankha-5a8b4b131
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Attaya-Suvannasankha-38810187
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - X / Twitter
x.com/ASuvannasankha
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - X / Twitter
x.com/suvannasankha
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Other
onclive.com/view/dr-suvannasankha-on-bispecific-antibodies-in-multiple-myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/IUCancerCenter/status/2064331881160511843
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Chulalongkorn University (Thailand)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University School of Medicine
Linda Dimeglio, MD
Indiana University School of Medicine
Patrick Loehrer, MD
Indiana University School of Medicine
Robert Tepper, MD
Indiana University School of Medicine
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens